G
Greg Yothers
Researcher at University of Pittsburgh
Publications - 190
Citations - 20700
Greg Yothers is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Colorectal cancer & Oxaliplatin. The author has an hindex of 56, co-authored 168 publications receiving 18158 citations. Previous affiliations of Greg Yothers include University of Florida & Yonsei University.
Papers
More filters
Posted Content
Visualizing adverse events in clinical trials using correspondence analysis with R-package visae
Marcio Alves Diniz,Gillian Gresham,Sungjin Kim,Michael Luu,N. Lynn Henry,Mourad Tighiouart,Greg Yothers,Patricia A. Ganz,Andre Rogatko +8 more
TL;DR: In this article, the authors proposed to apply stacked CA using contribution biplots as a tool to explore differences in AE data among treatments in clinical trials and developed a Shiny app built in an R-package, publicly available on Comprehensive R Archive Network (CRAN), to interactively investigate CA configurations.
Journal ArticleDOI
Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.
Greg Yothers,Alan P. Venook,Eiji Oki,Donna Niedzwiecki,Yan Lin,Michael Crager,Calvin Chao,Frederick L. Baehner,Norman Wolmark,Takayuki Yoshino +9 more
TL;DR: In this paper , the authors used pre-specified patient-specific meta-analysis (PSMA) methods to integrate the 12-gene Oncotype DX Colon Recurrence Score result (RS) with the clinical and pathology risk factors stage, T-stage, mis-match repair (MMR) status, and number of nodes examined to calculate individualized recurrence risk estimates.
Book ChapterDOI
Inference Guided Data Exploration
Greg Yothers,Allan R. Sampson +1 more
TL;DR: This work considers comparing two treatments using a given hypothesis test on the full sample and on all possible subsets, and separately considers restricting the subsets considered to be those defined based on half-intervals of a covariate.
Journal ArticleDOI
317MO Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: An ACCENT/IDEA pooled analysis of 12 trials
Claire Gallois,Q. Shi,J P Meyers,Thierry André,Timothy Iveson,Alberto Sobrero,Steven R. Alberts,Aimery de Gramont,Jeffrey A. Meyerhardt,Anthony F. Shields,T. Georges,Hans-Joachim Schmoll,Ioannis Souglakos,Rachel Kerr,Sara Lonardi,Greg Yothers,Takayuki Yoshino,Richard M. Goldberg,Julien Taieb,Demetrios Papamichael +19 more
Journal ArticleDOI
Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.
Katherine L. Pogue-Geile,Marion Joy,Ying Wang,Rim S. Kim,Patrick G. Gavin,Debora Fumagalli,Greg Yothers,Carmen J. Allegra,Ashok Srinivasan,Melanie Finnigan,Samuel A. Jacobs,Thomas J. George,Jennifer Marie Suga,Judith O. Hopkins,Naoyuki G. Saito,Norman Wolmark,Soonmyung Paik,Peter C. Lucas +17 more
TL;DR: The observation that IFNɣ low is associated with bev benefit in the entire C-08 cohort is unique to this study, and suggests that bev and ICB are most efficacious on different subsets of pts.